Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$284.98
At close: Jun 24 EDT
$284.98
0.000.00%
Pre-Market: 4:01 PM EDT
Comments
Loading...
Madrigal Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:MDGL | Benzinga
Madrigal Pharmaceuticals Inc has a consensus price target of $379.5 based on the ratings of 16 analysts. The high is $469 issued by Citigroup on February 27, 2025. The low is $150 issued by B of A Securities on April 22, 2024. The 3 most-recent analyst ratings were released by UBS, B. Riley Securities, and Canaccord Genuity on May 2, 2025, respectively. With an average price target of $446 between UBS, B. Riley Securities, and Canaccord Genuity, there's an implied 56.50% upside for Madrigal Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
B. Riley Securities
Canaccord Genuity
JMP Securities
Citigroup
1calculated from analyst ratings
Analyst Ratings for Madrigal Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/02/2025 | Buy Now | 60.71% | UBS | Eliana Merle48% | $441 → $458 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | 61.41% | B. Riley Securities | Mayank Mamtani71% | $422 → $460 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2025 | Buy Now | 47.38% | Canaccord Genuity | Edward Nash68% | $394 → $420 | Maintains | Buy | Get Alert |
| 04/24/2025 | Buy Now | 55.45% | JMP Securities | Jonathan Wolleben71% | $443 → $443 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/27/2025 | Buy Now | 64.57% | Citigroup | David Lebovitz64% | $378 → $469 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 42.12% | HC Wainwright & Co. | Ed Arce64% | $400 → $405 | Maintains | Buy | Get Alert |
| 01/14/2025 | Buy Now | 40.36% | HC Wainwright & Co. | Ed Arce64% | $390 → $400 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 49.84% | JMP Securities | Jonathan Wolleben71% | $427 → $427 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | — | Reiterates | → Neutral | Get Alert |
| 11/05/2024 | Buy Now | -17.19% | B. Riley Securities | Mayank Mamtani71% | $194 → $236 | Maintains | Neutral | Get Alert |
| 11/01/2024 | Buy Now | 54.75% | UBS | Eliana Merle48% | $411 → $441 | Maintains | Buy | Get Alert |
| 10/23/2024 | Buy Now | 22.82% | Oppenheimer | Jay Olson60% | $375 → $350 | Maintains | Outperform | Get Alert |
| 10/22/2024 | Buy Now | 36.85% | HC Wainwright & Co. | Ed Arce64% | $390 → $390 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | — | Reiterates | → Neutral | Get Alert |
| 08/08/2024 | Buy Now | 30.18% | Citigroup | David Lebovitz64% | $382 → $371 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 26.32% | Evercore ISI Group | Liisa Bayko70% | $405 → $360 | Maintains | Outperform | Get Alert |
| 07/23/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | — | Reiterates | → Neutral | Get Alert |
| 07/16/2024 | Buy Now | 35.1% | JMP Securities | Jonathan Wolleben71% | $381 → $385 | Maintains | Market Outperform | Get Alert |
| 06/28/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | — | Initiates | → Neutral | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen46% | — | Initiates | → Outperform | Get Alert |
| 05/10/2024 | Buy Now | -29.82% | B. Riley Securities | Mayank Mamtani71% | $270 → $200 | Maintains | Neutral | Get Alert |
| 05/08/2024 | Buy Now | 36.85% | HC Wainwright & Co. | Ed Arce64% | $425 → $390 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 34.04% | Citigroup | David Lebovitz64% | $389 → $382 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 33.69% | JMP Securities | Jonathan Wolleben71% | $397 → $381 | Maintains | Market Outperform | Get Alert |
| 04/22/2024 | Buy Now | -47.36% | B of A Securities | Alexandria Hammond45% | → $150 | Initiates | → Underperform | Get Alert |
| 03/20/2024 | Buy Now | 42.12% | Evercore ISI Group | Liisa Bayko70% | $325 → $405 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | 43.87% | UBS | Eliana Merle48% | $337 → $410 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 36.85% | TD Cowen | Ritu Baral38% | $349 → $390 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | -5.26% | B. Riley Securities | Mayank Mamtani71% | $155 → $270 | Upgrade | Sell → Neutral | Get Alert |
| 03/15/2024 | Buy Now | 36.5% | Citigroup | David Lebovitz64% | $382 → $389 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 39.31% | JMP Securities | Jonathan Wolleben71% | $351 → $397 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | 31.59% | Oppenheimer | Jay Olson60% | $320 → $375 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | 32.29% | Canaccord Genuity | Edward Nash68% | $338 → $377 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 49.13% | HC Wainwright & Co. | Ed Arce64% | $405 → $425 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 17.9% | Piper Sandler | Yasmeen Rahimi59% | → $336 | Reiterates | Overweight → Overweight | Get Alert |
| 03/12/2024 | Buy Now | 42.12% | HC Wainwright & Co. | Ed Arce64% | $275 → $405 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 18.6% | Canaccord Genuity | Edward Nash68% | $336 → $338 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 34.04% | Citigroup | David Lebowitz55% | → $382 | Initiates | → Buy | Get Alert |
| 03/01/2024 | Buy Now | 12.29% | Oppenheimer | Jay Olson60% | $300 → $320 | Maintains | Outperform | Get Alert |
| 02/27/2024 | Buy Now | -45.61% | B. Riley Securities | Mayank Mamtani71% | $204 → $155 | Downgrade | Neutral → Sell | Get Alert |
| 02/26/2024 | Buy Now | -45.61% | B. Riley Securities | Mayank Mamtani71% | → $155 | Downgrade | Neutral → Sell | Get Alert |
| 02/23/2024 | Buy Now | 21.76% | JMP Securities | Jonathan Wolleben71% | $347 → $347 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/16/2024 | Buy Now | 21.76% | JMP Securities | Jonathan Wolleben71% | $347 → $347 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/24/2024 | Buy Now | 17.9% | Piper Sandler | Yasmeen Rahimi59% | $305 → $336 | Maintains | Overweight | Get Alert |
| 11/14/2023 | Buy Now | 34.4% | JMP Securities | Jonathan Wolleben71% | → $383 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/13/2023 | Buy Now | -3.5% | HC Wainwright & Co. | Ed Arce64% | $225 → $275 | Maintains | Buy | Get Alert |
| 09/19/2023 | Buy Now | 14.04% | Evercore ISI Group | Liisa Bayko70% | $325 → $325 | Maintains | Outperform | Get Alert |
| 09/14/2023 | Buy Now | -21.05% | HC Wainwright & Co. | Ed Arce64% | → $225 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | -21.05% | HC Wainwright & Co. | Ed Arce64% | → $225 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | Buy Now | -21.4% | B. Riley Securities | Mayank Mamtani71% | → $224 | Reiterates | Neutral → Neutral | Get Alert |
| 09/05/2023 | Buy Now | -21.4% | B. Riley Securities | Mayank Mamtani71% | → $224 | Reiterates | Neutral → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 0.01% | Oppenheimer | Jay Olson60% | $350 → $285 | Maintains | Outperform | Get Alert |
| 07/18/2023 | Buy Now | 17.9% | Canaccord Genuity | Edward Nash68% | → $336 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 22.82% | Oppenheimer | Jay Olson60% | $300 → $350 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 17.9% | Canaccord Genuity | Edward Nash68% | → $336 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 17.9% | Canaccord Genuity | Edward Nash68% | $296 → $336 | Maintains | Buy | Get Alert |
| 02/27/2023 | Buy Now | 5.27% | Oppenheimer | Jay Olson60% | $250 → $300 | Maintains | Outperform | Get Alert |
| 01/05/2023 | Buy Now | 36.85% | JMP Securities | Jonathan Wolleben71% | $312 → $390 | Maintains | Market Outperform | Get Alert |
| 12/21/2022 | Buy Now | 18.25% | UBS | Eliana Merle48% | $161 → $337 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | 14.04% | Evercore ISI Group | Liisa Bayko70% | $175 → $325 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | -21.05% | HC Wainwright & Co. | Ed Arce64% | $170 → $225 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | -12.27% | Oppenheimer | Jay Olson60% | $170 → $250 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | 31.59% | Goldman Sachs | Andrea Tan40% | $178 → $375 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | 9.48% | JMP Securities | Jonathan Wolleben71% | $182 → $312 | Maintains | Market Outperform | Get Alert |
| 12/20/2022 | Buy Now | 10.53% | SVB Leerink | Mike Kratky66% | $145 → $315 | Maintains | Outperform | Get Alert |
| 07/08/2022 | Buy Now | -73.68% | B. Riley Securities | Mayank Mamtani71% | $131 → $75 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for Madrigal Pharmaceuticals (MDGL) stock?
The latest price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) was reported by UBS on May 2, 2025. The analyst firm set a price target for $458.00 expecting MDGL to rise to within 12 months (a possible 60.71% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Madrigal Pharmaceuticals (MDGL)?
The latest analyst rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) was provided by UBS, and Madrigal Pharmaceuticals maintained their buy rating.
When was the last upgrade for Madrigal Pharmaceuticals (MDGL)?
The last upgrade for Madrigal Pharmaceuticals Inc happened on March 15, 2024 when B. Riley Securities raised their price target to $270. B. Riley Securities previously had a sell for Madrigal Pharmaceuticals Inc.
When was the last downgrade for Madrigal Pharmaceuticals (MDGL)?
The last downgrade for Madrigal Pharmaceuticals Inc happened on February 27, 2024 when B. Riley Securities changed their price target from $204 to $155 for Madrigal Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Madrigal Pharmaceuticals (MDGL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Madrigal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Madrigal Pharmaceuticals was filed on May 2, 2025 so you should expect the next rating to be made available sometime around May 2, 2026.
Is the Analyst Rating Madrigal Pharmaceuticals (MDGL) correct?
While ratings are subjective and will change, the latest Madrigal Pharmaceuticals (MDGL) rating was a maintained with a price target of $441.00 to $458.00. The current price Madrigal Pharmaceuticals (MDGL) is trading at is $284.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
